Neurotensin: A Novel Mediator of Ovulation
神经降压素:一种新型的排卵调节剂
基本信息
- 批准号:10657389
- 负责人:
- 金额:$ 64.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-06 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAnimal ModelAntibodiesBioinformaticsCell physiologyCentral Nervous SystemComplementDataDefectDevelopmentEGF geneEndothelial CellsEvaluationEventFailureFc ReceptorFemale Contraceptive AgentsFemale infertilityFertilityFertilizationFutureGene Expression ProfilingGenesGonadotropinsHistologicHumanHuman Chorionic GonadotropinIn VitroInfertilityInjectionsLH ReceptorsLuteinizationMediatingMediatorMessenger RNAModelingMonkeysMotionMusNeuropeptidesNeurotensinNeurotensin ReceptorsNew AgentsOocytesOvarianOvarian FollicleOvarian TissueOvaryOvulationPathway interactionsPlayPregnancyPregnancy OutcomeProcessProgesteroneProstaglandinsReceptor SignalingRegulationReproductive ProcessReproductive systemRodentRoleRuptureSignal TransductionSystemTechnical ExpertiseTestingTimeVascular Endothelial CellWild Type MouseWomanangiogenesisantagonistcell typecollaborative approachdifferential expressionexperimental studyfemale fertilitygranulosa cellimplantationimproved outcomein vitro Modelin vivomouse modelneutralizing antibodynonhuman primatenoveloocyte qualityparacrinepreventreceptorreceptor expressionreproductive functionreproductive successresponsetheca celltranslational model
项目摘要
A woman’s fertility is dependent on the cascade of events leading up to ovulation. Defects in this ovulatory
process result in 25% of all female infertility cases, supporting the paramount role of ovulation in reproductive
success and providing a strong premise to explore mediators of the ovulatory process. We propose that
neurotensin is one of these pivotal regulators of the ovulatory process.
Ovulation is set in motion by the preovulatory LH surge which increases ovarian intrafollicular mediators
that act to bring about oocyte release. Our novel and exciting preliminary data indicate that neurotensin (NTS),
a small neuropeptide, is a key intrafollicular mediator of ovulation. This is based upon our findings that NTS is
one of the most differentially-expressed genes in the granulosa cells of the human ovulatory follicle, up to
15,000 fold after the ovulatory gonadotropin surge. Likewise, LH also rapidly and significantly increases NTS
mRNA in granulosa cells from rodent and monkey ovulatory follicles. Importantly, injection of a neurotensin
antibody into monkey preovulatory follicles blocked oocyte release resulting in luteinized unruptured follicles,
consistent with failure of ovulation. Similarly, mice lacking NTS expression form luteinized unruptured follicles
following LH/hCG administration, and a NTS receptor antagonist inhibits oocyte release in a novel in vitro
model of mouse ovulation. Yet, other than our preliminary data, nothing is known regarding the temporal
expression of NTS receptors or the function of NTS in ovulation and female fertility. These questions will be
addressed in this proposal through a collaborative approach utilizing the exceptional backgrounds, technical
expertise, and models of the Project Leaders. We will make use of a high-impact, translational model where
the granulosa and theca from human periovulatory follicles will be collected prior to and at three designated
times after hCG (early, late and postovulatory) to complement in vivo and in vitro studies performed with mice
and monkeys. The regulation of NTS and NTS receptor expression in the ovulatory follicle will be illuminated
and compared across women, monkeys and mice in Aim 1. The ovulatory functions stimulated by NTS in
granulosa, theca, cumulus, and endothelial cells of the follicle will be elucidated in Aim 2. The actions of NTS
on ovulation, as well as other key reproductive processes, will be revealed in mice and monkeys using mice
lacking NTS expression, NTS receptor antagonists, and NTS-neutralizing antibodies in Aim 3. A major strength
of this proposal is the collaborative interactions between Dr. Curry and Dr. Duffy to address the function of NTS
and its receptors in periovulatory events across multiple species, including exceptional human ovarian tissues
and in vivo studies of non-human primates, an animal model with high relevance to human reproductive
function. Thus, there is an exceptional degree of significance in understanding the basic tenets of oocyte
release which provides a fundamental platform to either improve outcomes for infertile women or conversely
provide targets to prevent oocyte release for female contraception.
女性的生育能力取决于导致排卵的一系列事件。这个排卵器有缺陷
过程导致25%的女性不孕,支持排卵在生殖中的重要作用
并为探索排卵过程的介体提供了有力的前提。我们建议
神经降压素是排卵过程中的关键调节因子之一。
排卵是由排卵前的促黄体生成素激增启动的,它增加了卵泡内介质。
导致卵子释放的行为。我们新颖而令人兴奋的初步数据表明,神经降压素(NTS),
一种小的神经肽,是卵泡内排卵的关键介质。这是基于我们的发现,NTS是
在人类排卵卵泡的颗粒细胞中差异表达最多的基因之一,
排卵期促性腺激素激增后15,000倍。同样,促黄体生成素也迅速而显著地增加了NTS
啮齿动物和猕猴排卵卵泡颗粒细胞中的mRNA。重要的是,注射神经降压素
进入猴子排卵前卵泡的抗体阻止了卵母细胞的释放,导致黄素化的未破裂卵泡,
与排卵失败相一致。同样,缺乏NTS表达的小鼠形成黄素化的未破裂卵泡
在给予黄体生成素/人绒毛膜促性腺激素后,NTS受体拮抗剂在体外抑制卵母细胞的释放
小鼠排卵模型。然而,除了我们的初步数据,关于时间上的
NTS受体的表达及其在排卵和女性生育中的作用这些问题将是
在本建议书中通过利用特殊背景、技术
项目负责人的专业知识和模式。我们将使用高影响力的翻译模式,其中
人类排卵周围卵泡的颗粒和卵膜将在指定的三个月之前和之后收集
在小鼠体内和体外进行的hCG补体时间(早期、晚期和排泄后)研究
还有猴子。将阐明NTS及其受体在排卵卵泡中的表达调控。
并在目标1中对女性、猴子和小鼠进行了比较。NTS刺激的排卵功能
目标2将阐明卵泡的颗粒、膜、卵丘和内皮细胞。NTS的作用
关于排卵以及其他关键生殖过程的研究将在小鼠和猴子身上揭示。
在AIM中缺乏NTS表达、NTS受体拮抗剂和NTS中和抗体3.主要优势
这项提议的一部分是库里博士和达菲博士之间的合作互动,以解决NTS的功能
及其受体在多个物种的排卵事件中的作用,包括特殊的人类卵巢组织
对非人类灵长类动物的活体研究,这是一种与人类生殖高度相关的动物模型
功能。因此,了解卵母细胞的基本原理具有非常重要的意义。
释放,为改善不孕妇女的结局或相反提供了一个基本的平台
为女性避孕提供防止卵母细胞释放的目标。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas E Curry其他文献
Thomas E Curry的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas E Curry', 18)}}的其他基金
Kentucky BIRCWH Program: Training the Next Generation of Women's Health Scholars
肯塔基州 BIRCWH 计划:培训下一代女性健康学者
- 批准号:
10428147 - 财政年份:2022
- 资助金额:
$ 64.5万 - 项目类别:
Kentucky BIRCWH Program: Training the Next Generation of Women's Health Scholars
肯塔基州 BIRCWH 计划:培训下一代女性健康学者
- 批准号:
10858550 - 财政年份:2022
- 资助金额:
$ 64.5万 - 项目类别:
Kentucky BIRCWH Program: Training the Next Generation of Women's Health Scholars
肯塔基州 BIRCWH 计划:培训下一代女性健康学者
- 批准号:
10649610 - 财政年份:2022
- 资助金额:
$ 64.5万 - 项目类别:
Supplement for Kentucky BIRCWH Program: Training the Next Generation of Women's Health Scholars
肯塔基州 BIRCWH 计划补充材料:培训下一代女性健康学者
- 批准号:
10682952 - 财政年份:2022
- 资助金额:
$ 64.5万 - 项目类别:
Center for Appalachian Research in Environmental Sciences-Pilot Project Program (PPP)
阿巴拉契亚环境科学研究中心试点项目计划 (PPP)
- 批准号:
10610036 - 财政年份:2017
- 资助金额:
$ 64.5万 - 项目类别:
Ovulation and Luteal Formation in Rodents Monkeys and Women
啮齿动物、猴子和女性的排卵和黄体形成
- 批准号:
9325047 - 财政年份:2014
- 资助金额:
$ 64.5万 - 项目类别:
Ovulation and Luteal Formation in Rodents Monkeys and Women
啮齿动物、猴子和女性的排卵和黄体形成
- 批准号:
8609207 - 财政年份:2014
- 资助金额:
$ 64.5万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 64.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 64.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 64.5万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 64.5万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 64.5万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 64.5万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 64.5万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 64.5万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 64.5万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 64.5万 - 项目类别: